fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Merck Completes Spinoff Of Organon & Co. Aiming To Create 2 patient-focused Companies

By John F. Heerdink, Jr.

Reportedly, Merck & Co., Inc.  (MRK) has completed the spinoff of Organon & Co. The spinoff aims to create two patient-focused companies with an enhanced strategic and operational focus, simplified operating models, improved agility, improved financial profiles, and optimized capital structures.

“Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value. With leadership in our growth pillars and our robust pipeline, Merck is well positioned for strong long-term growth, with scientific innovation remaining the source of our value creation,” stated Rob Davis, president, Merck.

The transaction is expected to deliver benefits for both Merck and Organon and create value for Merck shareholders. Fractional shares of Organon common stock for the distribution were not issued, instead, the holders of Merck common shares received cash instead of any fractional shares of Organon common stock. Shares of Organon will be listed under the New York Stock Exchange under the symbol “OGN”. Shares of Merck will continue to trade under the symbol “MRK”.

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.


(Read Original Story: Merck Announces Completion of Organon & Co. Spinoff in Business Wire)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us